Celadon Pharmaceuticals PLC (CEL) - Net Assets
Based on the latest financial reports, Celadon Pharmaceuticals PLC (CEL) has net assets worth GBX2.45 Million GBX (≈ $298.46 USD) as of June 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX8.46 Million ≈ $1.03K USD) and total liabilities (GBX6.01 Million ≈ $731.12 USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Celadon Pharmaceuticals PLC tangible equity quality to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX2.45 Million |
| % of Total Assets | 28.99% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 3015.09 |
Celadon Pharmaceuticals PLC - Net Assets Trend (2019–2023)
This chart illustrates how Celadon Pharmaceuticals PLC's net assets have evolved over time, based on quarterly financial data. See CEL defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Celadon Pharmaceuticals PLC (2019–2023)
The table below shows the annual net assets of Celadon Pharmaceuticals PLC from 2019 to 2023. For live valuation and market cap data, see Celadon Pharmaceuticals PLC (CEL) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | GBX3.18 Million ≈ $387.04 |
-54.80% |
| 2022-12-31 | GBX7.04 Million ≈ $856.20 |
+9.77% |
| 2021-12-31 | GBX6.41 Million ≈ $780.00 |
+6373.22% |
| 2020-12-31 | GBX99.03K ≈ $12.05 |
+187.28% |
| 2019-12-31 | GBX-113.47K ≈ $-13.81 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Celadon Pharmaceuticals PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3061722700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX642.00K | 20.33% |
| Other Comprehensive Income | GBX7.74 Million | 245.19% |
| Other Components | GBX25.50 Million | 807.60% |
| Total Equity | GBX3.16 Million | 100.00% |
Celadon Pharmaceuticals PLC Competitors by Market Cap
The table below lists competitors of Celadon Pharmaceuticals PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
WORK Medical Technology Group LTD Ordinary Shares
NASDAQ:WOK
|
$112.75K |
|
Croma Security Solutions Group Plc
LSE:CSSG
|
$113.08K |
|
Block Energy PLC
LSE:BLOE
|
$114.32K |
|
Cadogan Petroleum plc
LSE:CAD
|
$114.58K |
|
Rockfire Resources plc
LSE:ROCK
|
$111.37K |
|
Induction Healthcare Group PLC
LSE:INHC
|
$111.33K |
|
Ceps PLC
LSE:CEPS
|
$111.15K |
|
Stora Enso Oyj ser. R
ST:STE-R
|
$110.88K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Celadon Pharmaceuticals PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 7,675,000 to 3,158,000, a change of -4,517,000 (-58.9%).
- Net loss of 7,140,000 reduced equity.
- New share issuances of 2,976,000 increased equity.
- Other comprehensive income increased equity by 6,313,000.
- Other factors decreased equity by 6,666,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-7.14 Million | -226.09% |
| Share Issuances | GBX2.98 Million | +94.24% |
| Other Comprehensive Income | GBX6.31 Million | +199.91% |
| Other Changes | GBX-6.67 Million | -211.08% |
| Total Change | GBX- | -58.85% |
Book Value vs Market Value Analysis
This analysis compares Celadon Pharmaceuticals PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 262.63x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | GBX-0.02 | GBX13.40 | x |
| 2020-12-31 | GBX0.02 | GBX13.40 | x |
| 2021-12-31 | GBX0.13 | GBX13.40 | x |
| 2022-12-31 | GBX0.13 | GBX13.40 | x |
| 2023-12-31 | GBX0.05 | GBX13.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Celadon Pharmaceuticals PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -226.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -9520.00%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 2.92x
- Recent ROE (-226.09%) is above the historical average (-388.03%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | GBX-140.35K |
| 2020 | -1412.59% | 0.00% | 0.00x | 38.89x | GBX-1.41 Million |
| 2021 | -74.61% | -239150.00% | 0.00x | 1.03x | GBX-5.42 Million |
| 2022 | -226.85% | -72545.83% | 0.00x | 1.73x | GBX-18.18 Million |
| 2023 | -226.09% | -9520.00% | 0.01x | 2.92x | GBX-7.46 Million |
Industry Comparison
This section compares Celadon Pharmaceuticals PLC's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,104,382,936
- Average return on equity (ROE) among peers: 18.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Celadon Pharmaceuticals PLC (CEL) | GBX2.45 Million | 0.00% | 2.45x | $112.25K |
| Allergy Therapeutics (AGY) | $-4.40 Million | 0.00% | 0.00x | $5.23 Million |
| Animalcare Group Plc (ANCR) | $77.89 Million | 1.54% | 0.37x | $2.78 Million |
| Alliance Pharma plc (APH) | $282.49 Million | 2.59% | 0.78x | $4.26 Million |
| Chill Brands Group PLC (CHLL) | $-1.23 Million | 0.00% | 0.00x | $168.61K |
| Eco Animal Health Group Plc (EAH) | $60.29 Million | 4.34% | 0.16x | $726.44K |
| HUTCHMED China Ltd (HCM) | $1.25 Billion | 36.57% | 0.40x | $16.58 Million |
| Hikma Pharmaceuticals PLC (HIK) | $847.85 Million | 11.79% | 1.04x | $39.26 Million |
| Haleon PLC (HLN) | $16.22 Billion | 8.89% | 1.12x | $361.92 Million |
| Indivior PLC (INDV) | $203.00 Million | 100.99% | 8.02x | $18.79 Million |
About Celadon Pharmaceuticals PLC
Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products. Its products used to treat chronic pain, as well as autism spectrum disorders. Celadon Pharmaceuticals Plc was founded in 2018 and is headquartered in London, the United Kingdom.